<unk>  blood plasma levels are expected to increase when combined with inhibitors of the liver enzyme CYP3A4 and lowered when combined with inductors of this enzyme. Being a CYP3A4 inhibitor itself,<unk>  could also increase plasma levels of pharmaceuticals that are metabolized by CYP3A4. This effect has been observed with dexamethasone, the anti-cancer drugs docetaxel and etoposide, and to a minor (not clinically significant) extent with levonorgestrel, erythromycin and midazolam.
Netupitant
Oprelvekin
Aprepitant
Bosentan
Macitentan
Ezlopitant
Eptifibatide
Tafamidis